The effects of intravenously administered 8-(3-diethylaminopropyl)-6,6-dimethyl-(2-phenyl-1H-imidazo (4,5H))-isoquinoline-7,9-(6H)-dione dihydrochloride (AR-LH31) on experimentally induced
ventricular tachycardia were studied in dogs.
Ventricular tachycardia was produced in 6 anaesthetised dogs by the
intravenous injection of
ouabain (66.7 +/- 4.9 mg/kg).
AR-LH31 administered by increasing bolus
injections every 5 min completely suppressed the
ventricular tachycardia with a return to sinus rhythm in 1 out of 6 dogs, with a partial return of sinus beats in a second dog. There was no return to sinus rhythm in the 4 remaining dogs after doses ranging from 1.75 to 15.75 mg/kg. Observations were made in 9 conscious dogs 22-24 hours after
ligation of the anterior descending branch of the left coronary artery when a
ventricular tachycardia was present. The administration of
AR-LH31 by bolus
intravenous injection in 4 dogs did not abolish the
arrhythmia in any dog but increased the number of sinus beats. In 3 out of 4 dogs after a cumulative dose of 7.75 mg/kg, 60% of ventricular beats were of sinus origin. The effects of larger doses could not be studied be cause of adverse effects. In 5 dogs the administration of
AR-LH31 by constant
intravenous infusion at 16 mg/kg/h restored sinus rhythm in all dogs after a mean dose of 9.9 +/- 0.9 mg/kg. These studies indicate that
AR-LH31 has
anti-arrhythmic activity in dogs and highlight the importance of the method of administration in determining the effects of a
drug.